Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Condition(s): H9N2 Pandemic Influenza Last Updated: February 14, 2013Active, not recruiting